FrancophonIA/ELRC3.0 huggingface dataset:
English: You should usually receive your Docefrez infusion every three weeks.
Slovenian: Infuzijo Docefrez-a običajno prejmete vsake tri tedne.
English: 4.1.4 Remove the syringe and needle and shake well for complete solubilisation of powder.
Slovenian: 4.1.4 Odstranite brizgo in iglo ter dobro pretresite, za popolno solubilizacijo praška.
English: For combination with trastuzumab, adverse events (all grades) reported in ≥ 10% are displayed.
Slovenian: Pri kombinaciji s trastuzumabom so predstavljeni neželeni učinki (vseh stopenj) poročani v > 10 %.
English: 75 mg/m2 (see sections 4.4 and 5.2).
Slovenian: 75 mg/m2 (glejte poglavji 4.4 in 5.2).
English: Each pack contains: 1 powder vial and 1 solvent vial.
Slovenian: Vsako pakiranje vsebuje: 1 vialo s praškom in 1 vialo z vehiklom.
English: • decreased number of platelets (increased risk of unexpected bleedings)
Slovenian: • znižano število trombocitov (povečana nevarnost nepričakovane krvavitve);
English: Intravenous use, after reconstitution and dilution.
Slovenian: Intravenozna uporaba, po pripravi in razredčitvi.
English: Docetaxel plus trastuzumab1 n=92
Slovenian: Docetaksel in trastuzumab1 n = 92
English: The application is based on a reference medicinal product for which no safety concerns requiring additional risk minimization activities have been identified.
Slovenian: Vloga temelji na referenčnem zdravilu, za katerega niso bila ugotovljena varnostna vprašanja,
English: Symptoms such as early abdominal pain and tenderness, fever, diarrhoea, with or without neutropenia, may be early manifestations of serious gastrointestinal toxicity and should be evaluated and treated promptly.
Slovenian: Simptomi kot so abdominalne bolečine in občutljivost, zvišana telesna temperatura, driska z ali brez nevtropenije, so lahko zgodnja manifestacija resne gastrointestinalne toksičnosti ter jih je potrebno nemudoma ovrednotiti in zdraviti.
English: The main test method used to determine HER2 positivity in this pivotal study was immunohistochemistry (IHC).
Slovenian: HER2-pozitivnosti v tej odločilni študiji je bila imunohistokemija (IHK).
English: 4.1.3 Inject the entire contents of the syringe into the corresponding Docefrez vial.
Slovenian: 4.1.3 Vbrizgajte celotno vsebino injekcijske brizge v ustrezno vialo Docefreza.
English: What Docefrez looks like and contents of the pack
Slovenian: Kakšen je Docefrez in vsebina pakiranja
English: Before each Docefrez dose, you will have blood tests to check that your blood cell counts and liver function are adequate.
Slovenian: Pred vsakim odmerkom Docefrez boste imeli pregled krvi za preverjanje ali je število vaših rdečih krvnih celic in delovanje jeter primerno.
English: Docetaxel1 n=94
Slovenian: Docetaksel1 n = 94
English: Survival data, median time to progression and response rates for two arms of the study are illustrated in the following table.
Slovenian: Podatke o preživetju, mediano časa do napredovanja in delež odziva v dveh krakih te raziskave prikazuje naslednja preglednica:
English: • dripping or running nose; inflammation of the throat and nose*
Slovenian: • kapljanje iz nosu; vnetje grla in nosu*;
English: Detailed information on this medicine is available on the European Medicines Agency web site: ://www.ema.europa.eu
Slovenian: Podrobne informacije o zdravilu je na voljo na spletni strani Evropske agencije za zdravila (EMA): ://www.ema.europa.eu
English: Docefrez is incompatible with PVC equipment or devices.
Slovenian: Docefrez ni združljiv s PVC opremo ali napravami.
English: Dry skin; Desquamation
Slovenian: Suha koža, luščenje
English: Acute leukaemia / Myelodysplastic syndrome
Slovenian: Akutna levkemija / mielodisplastični sindrom
English: • raised liver enzymes (in blood tests)
Slovenian: • krvavitve; • povišani jetrni encimi (v krvnih testih);
English: Congestive Heart Failure (CHF) has been reported in 18 of 1276 patiens during the follow-up period.
Slovenian: Opisano je bilo tudi kongestivno srčno popuščanje pri 18 od 1276 bolnicah v obdobju spremljanja.
English: The secondary endpoint, PFS, demonstrated a 29% risk reduction of progression or death and a 22 month improvement in median PFS (35.5 months for TPF and 13.1 for PF).
Slovenian: (PBN), je pokazala 29 % zmanjšanje tveganja za napredovanje ali smrt ter 22-mesečno izboljšanje medianega PBN (35,5 mesecev pri TPF in 13,1 pri PF).
English: Overall, quality of life (QoL) and clinical benefit results consistently indicated improvement in favor of the TCF arm.
Slovenian: V celoti pa rezultati kakovosti življenja in klinične koristi dosledno kažejo izboljšanje v kraku s TCF.
English: In non clinical studies, docetaxel has genotoxic effects and may alter male fertility (see section 5.3).
Slovenian: V nekliničnih študijah je bilo dokazano, da ima docetaxel genotoksične učinke in lahko vpliva na plodnost moških (glejte oddelek 5.3).
English: Do not use any PVC equipment or device.
Slovenian: Ne uporabljajte opreme ali naprav iz PVC-ja.
English: If you have any further questions on the use of this medicine, ask your doctor or nurse.
Slovenian: V primeru dodatnih vprašanj o uporabi izdelka, se obrnite na zdravnika ali medicinsko sestro.
English: The median cumulative dose to treatment discontinuation was more than 1,000 mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Slovenian: Mediani kumulativni odmerek do prekinitve zdravljenja je bil več kot 1.000 mg/m2 in mediani čas do izginotja zastoja tekočine 16,4 tedna (razpon od 0 do 42 tednov).
English: If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse.
Slovenian: Če kateri izmed stranskih učinkov postane resnejši ali če opazite stranske učinke, ki niso navedeni v tej brošuri, povejte zdravniku ali medicinski sestri.
English: Patients treated with TPF experienced significantly less deterioration of their Global health score compared to those treated with PF (p=0.01, using the EORTC QLQ-C30 scale).
Slovenian: Pri bolnikih, zdravljenih s TPF, se je lestvica globalnega zdravja signifikantno manj poslabšala kot pri tistih, ki so bili zdravljeni s PF (p = 0,01, uporabljena je bila lestvica EORTC QLQ-C30).
English: • headache* , insomnia*
Slovenian: • glavobol* , nespečnost*;
English: • feeling of numbness or pins and needles, taste disturbances (due to nerve damage)
Slovenian: • občutek otrplosti ali mravljincev, motnje okusa (zaradi poškodovanih živcev);
English: Reduced tolerance of docetaxel may occur, even at lower doses.
Slovenian: Celo pri zmanjšanih odmerkih se lahko pojavi zmanjšanje tolerance docetaksela.
English: - If you have any further questions, ask your doctor or nurse.
Slovenian: Če imate dodatna vprašanja, se posvetujte z zdravnikom ali z bolnišničnim farmacevtom.
English: Tell your doctor if you have: - heart problems - liver problems - kidney problems
Slovenian: Zdravnika opozorite v primeru: težav s srcem težav z jetri težav z ledvicami
English: Based on the required dose for the patient expressed in mg, aseptically withdraw the corresponding volume from the appropriate number of reconstituted solutions using graduated syringes fitted with a needle.
Slovenian: Odvisno od potrebnega odmerka za pacienta v mg, aseptično izvlecite potrebno količino iz ustreznega števila pripravljenih raztopin s pomočjo oštevilčene brizge z iglo.
English: The benefit/risk ratio for TAC in patients with 4+ nodes was not defined fully at the interim analysis (see section 5.1).
Slovenian: Pri bolnicah s 4+ bezgavkami razmerje korist/tveganje za TAC v vmesnih analizah ni bilo docela definirano (glejte poglavje 5.1).
English: Detailed information on this product is available on the website of the European Medicines Agency (EMA): http://www.ema.europa.eu.
Slovenian: Podrobne informacije o zdravilu so na voljo na spletni strani Evropske agencije za zdravila (EMA): ://www.ema.europa.eu.
English: 4.2 Preparation of the infusion solution
Slovenian: 4.2 Priprava infuzijske raztopine
English: The required number of Docefrez powder vials should be allowed to reach room temperature (between 15°C - 25°C) for 5 minutes.
Slovenian: Ustrezno število vial s praškom Docefrez pustite stati na sobni temperaturi (od 15°C do 25°C) 5 minut.
English: TAC-treated patient subsets according to prospectively defined major prognostic factors were analyzed:
Slovenian: Podskupine bolnic, zdravljenih s TAC, so analizirali po prospektivno opredeljenih prognostičnih dejavnikih:
English: TAC = docetaxel, doxorubicin and cyclophosphamide FAC = 5-fluorouracil, doxorubicin and cyclophospamide CI = confidence interval; ER = estrogen receptor PR = progesterone receptor
Slovenian: TAC = docetaksel, doksorubicin in ciklofosfamid FAC = 5-fluorouracil, doksorubicin in ciklofosfamid IZ = interval zaupanja, ER = estrogenski receptor PR = progesteronski receptor
English: If you are a man being treated with Docefrez you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility.
Slovenian: Če ste moški, ki se zdravi z Docefrezom, se vam svetuje, da med zdravljenjem in vsaj 6 mesecev po njem ne oplodite svoje partnerice ter, da poiščete nasvet glede konzervacije sperme, kajti Docetaksel lahko vpliva na plodnost moškega.
English: Women of childbearing potential /contraception:
Slovenian: Ženske v rodni dobi/kontracepcija
English: The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20-115 mg/m2 in phase I studies.
Slovenian: Farmakokinetiko docetaksela so ocenili pri onkoloških bolnikih po uporabi 20-115 mg/m2 v študijah I.
English: Overall response rate (%)
Slovenian: Celotni delež odziva (%)
English: See leaflet for further information.
Slovenian: Za dodatne informacije glejte brošuro.
English: • inflammation of the eye or increased watering of the eyes
Slovenian: • vnetje oči ali povečano solzenje;
English: The most frequent side effects of Docefrez, when given alone, are decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness (all very common).
Slovenian: Najpogostejši neželeni učinek zdravila Docefrez ob samostojni uporabi, je zmanjšanje število rdečih krvnih celic ali belih krvnih celic, plešavost, slabost, bruhanje, vnetja v ustni votlini, diareja in utrujenost (vsi zelo pogosti).
English: Severe nail disorders are characterised by hypo- or hyperpigmentation and sometimes pain and onycholysis.
Slovenian: Za hudo prizadetost nohtov so značilni hipo ali hiperpigmentacija in včasih bolečine in oniholiza.
English: A drug interaction study performed in patients receiving ketoconazole and docetaxel showed that the clearance of docetaxel was reduced by half by ketoconazole, probably because the metabolism of docetaxel involves CYP3A4 as a major (single) metabolic pathway.
Slovenian: Študija interakcije, ki so jo izvajali pri bolnikih, ki so jemali ketokonazol in docetaksel, je pokazala, da je ketokonazol za polovico zmanjšal očistek docetaksela, verjetno zato ker metabolizem docetaksela vključuje CYP3A4 kot glavno (edino) metabolično pot.
English: 4.2.1 More than one vial of reconstituted solution may be necessary to obtain the required dose for the patient.
Slovenian: 4.2.1 Za pripravo potrebnega odmerka za pacienta boste morda morali uporabiti več kot eno vialo.
English: The solvent is a viscous, clear and colourless solution.
Slovenian: Vehikel je viskozna, bistra in brezbarvna raztopina.
English: 4.2.5 As with all parenteral products, Docefrez reconstituted solution and solution for infusion should be visually inspected prior to use, solutions containing a precipitate should be discarded.
Slovenian: 4.2.5 Tako kot vsa zdravila za parenteralno uporabo je treba tudi osnovno raztopino in raztopino za infundiranje Docefrez pred uporabo pregledati; če vsebuje precipitat, jo je treba zavreči.
English: Hazard ratio: 1.032 [95% CI: 0.876; 1.216]
Slovenian: Razmerje tveganj: 1,032 [95 % IZ: 0,876, 1,216]
English: The reconstituted solution contains ~ 24 mg/ml docetaxel, corresponding with an extractable volume of approximately 20 mg/0.84 ml and 80 mg/3.36 ml.
Slovenian: Pripravljena raztopina vsebuje približno ~ 24 mg/ml docetaksela, kar ustreza izločeni količini od približno 20 mg/0,84 ml in 80 mg/3,36 ml.
English: In the case of severe neutropenia (<500 cells/mm3 for seven days or more) during a course of docetaxel therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate symptomatic measures are recommended (see section 4.2).
Slovenian: Če se med zdravljenjem z docetakselom pojavi huda nevtropenija (< 500 celic/mm3 sedem dni ali več), je med naslednjimi ciklusi priporočljivo zmanjšati odmerek ali uporabiti ustrezne simptomatske ukrepe (glejte poglavje 4.2).
English: Uncommon side effects:
Slovenian: Neobičajni stranski učinki:
English: Treatment difference: 7.1% [95% CI: 0.7; 13.5]
Slovenian: Razlika zdravljenj: 7,1 % [95 % IZ: 0,7, 13,5]
English: 95% CI p=
Slovenian: 95 % IZ p =
English: • fungal infection of the mouth (oral candidiasis)
Slovenian: • glivične infekcije ust (oralna kandidoza);
English: The benefit/risk ratio was not defined fully in patients with 4 and more positive nodes at this analysis stage.
Slovenian: Na tej stopnji analize razmerje med koristjo in tveganjem ni bilo povsem definirano pri bolnicah s 4 ali več pozitivnimi bezgavkami.
English: Fluid retention (severe/lifethreatening: 1%).
Slovenian: zastajanje tekočine (hudo/smrtno nevarno: 1 %)
English: Docetaxel was administered as a 1-hour infusion, all other drugs were given intravenously on day 1 every three weeks.
Slovenian: Zdravilo Docetaksel je bilo uporabljeno v 1-urni infuziji, vsa druga zdravila pa intravensko 1. dan na tri tedne.
English: Locoregional therapy with radiation was delivered either with a conventional fraction (1.8 Gy-2.0 Gy once a day, 5 days per week for a total dose of 66 to 70 Gy), or accelerated/hyperfractionated regimens of radiation therapy (twice a day, with a minimum interfraction interval of 6 hours, 5 days per week).
Slovenian: Lokoregionalno terapijo z obsevanjem so aplicirali bodisi s konvencionalno frakcijo (1,8 Gy - 2,0 Gy enkrat na dan, 5 dni na teden v celotnem odmerku 66 do 70 Gy), ali s pospešenimi/ hiperfrakcioniranimi shemami obsevalnega zdravljenja (dvakrat na dan, z minimalnim intervalom med frakcijama 6 ur, 5 dni na teden).
English: Side effects may occur with certain frequencies, which are defined as follows: - very common: affects more than 1 user in 10 - common: affects 1 to 10 users in 100 - uncommon: affects 1 to 10 users in 1,000 - rare: affects 1 to 10 users in 10,000 - very rare: affects less than 1 user in 10,000 - not known: frequency cannot be estimated from the available data.
Slovenian: Stranski učinki se lahko pojavijo različno pogosto, kar je določeno kot sledi: - zelo pogosti se pojavijo pri več kot 1 uporabniku na 10 uporabnikov - pogosti: učinek pri 1 do 10 uporabnikov na 100 uporabnikov - občasni: učinek pri 1 do 10 uporabnikov na 1.000 uporabnikov - redki: učinek pri 1 do 10 uporabnikov na 10.000 uporabnikov - zelo redki: učinek pri manj kot 1 uporabniku na 10.000 uporabnikov
English: In the pivotal SCCHN studies, patients who experienced complicated neutropenia (including prolonged neutropenia, febrile neutropenia, or infection), it was recommended to use G-CSF to provide prophylactic coverage (e.g. day 6-15) in all subsequent cycles.
Slovenian: V ključni SCCHN študiji pri bolnikih, pri katerih se je pojavila komplicirana nevtropenija (ki vključuje dolgotrajno nevtropenijo, fibrilno nevtropenijo ali okužbo), je bilo priporočeno, naj se v vseh naslednjih ciklih za profilaktično kritje (na primer med 6. in 15. dnem) uporablja G-CSF.
English: Post-Menopausal * a hazard ratio (TAC/FAC) of less than 1 indicates that TAC is associated with a longer disease free survival compared to FAC.
Slovenian: Po menopavzi *a razmerje ogroženosti Vrednost (TAC/FAC) manj kot 1 pomeni, da je kombinacija TAC povezana z daljšim preživetjem brez bolezni kot kombinacija FAC.
English: Tell your doctor or nurse immediately during or shortly after the infusion, you notice any of the following symptoms of allergic reactions (very common): - flushing, skin reactions, itching - chest tightness, difficulty in breathing - fever or chills - back pain - low blood pressure.
Slovenian: Zdravnika ali medicinsko sestro nemudoma med ali po infuziji obvestite, če opazite katerega izmed naslednjih simptomov alergijske reakcije (zelo običajno): - rdečica, kožne reakcije, srbenje; - občutek utesnjenosti v prsih, težave z dihanjem; - vročica ali mrzlica; - bolečine v hrbtu;
English: The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates ≥ 10% higher in patients who were 65 years of age or older compared to younger patients.
Slovenian: Incidenca naslednjih neželenih učinkov (vse stopnje)letargije, stomatitisa in nevtropenične okužbe - je bila pri bolnikih, starih 65 let ali več, > 10 % večja kot pri mlajših bolnikih.
English: Peripheral sensory neuropathy was observed to be ongoing during follow-up in 12 patients out of the 83 patients with peripheral sensory neuropathy at the end of the chemotherapy.
Slovenian: Še prisotno periferno senzorično nevropatijo so pri spremljanju zabeležili pri 12 od 83 bolnicah, ki so imeli periferno senzorično nevropatijo ob koncu kemoterapije.
English: Hazard ratio*
Slovenian: Razmerje tveganj*
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hrs at 2 to 8°C, unless reconstitution and further dilution has taken place in controlled and validated aseptic conditions.
Slovenian: Če raztopine ne uporabimo takoj, moramo zagotoviti ustrezen čas roka uporabe in pogoje shranjevanja pred uporabo, po navadi je to do 24 ur pri temperaturi od 2 do 8 °C, razen če je bila v nadzorovanih in ustreznih aseptičnih pogojih raztopina znova pripravljena in razredčena.
English: Patients receiving TCF should be closely monitored, (see sections 4.2 and 4.8).
Slovenian: Bolnike, ki prejemajo TCF, je treba natančno nadzirati (glejte poglavji 4.2 in 4.8).
English: The incidence of related fever, diarrhoea, anorexia, and peripheral oedema occurred at rates ≥ 10% higher in patients who were 75 years of age or greater versus less than 65 years.
Slovenian: Incidenca z zdravljenjem povezane zvišane telesne temperature, diareje, anoreksije in perifernih edemov se je pojavljala > 10 % večkrat pri bolnikih nad 75 let v primerjavi z mlajšimi od 65 let.
English: In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as ciclosporine, terfenadine, ketoconazole, erythromycin and troleandomycin.
Slovenian: Študije in vitro so pokazale, da lahko presnovo docetaksela spremeni sočasna uporaba zdravil, ki inducirajo ali inhibirajo citokrom P450-3A ali se z njim presnavljajo (in ga tako lahko kompetitivno inhibirajo), kot so ciklosporin, terfenadin, ketokonazol, eritromicin in troleandomicin.
English: Important information about some of the ingredients of Docefrez
Slovenian: Pomembne informacije o sestavinah v Docefrez
English: Neutropenia (Grade 4) Febrile neutropenia Neutropenic infection
Slovenian: Nevtropenija (4. stopnje) Febrilna nevtropenija
English: Neutropenic infection
Slovenian: nevtropenična okužba
English: In the node positive study (TAX316) one patient in each treatment arm died because of cardiac failure.
Slovenian: V študijah pri bolnicah s pozitivnimi bezgavkami (TAX 316), je zaradi srčnega popuščanja umrla po ena bolnica v vsakem kraku.
English: Immune system disorders Some cases of anaphylactic shock, sometimes fatal, have been reported.
Slovenian: Poročali so o nekaj primerih anafilaktičnega šoka, včasih usodnega.
English: (G3/4 2.7%).
Slovenian: (S3/4 2.7%).
English: Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
Slovenian: Docetaksel se metabolizira s CYP3A4, za prednizon pa je znano, da inducira
English: Age category 1 <50 years
Slovenian: Starostna kategorija 1 < 50 let ≥ 50 let
English: • decreased number of white blood cells (may make you more prone to infections)
Slovenian: • znižano število belih krvnih celic (dovzetnost za infekcije);
English: Based on a population pharmacokinetic analysis, there are no special instructions for use in the elderly.
Slovenian: Starostniki Za uporabo pri starostnikih glede na analizo farmakokinetike na populaciji ni posebnih navodil.
English: There is no relevant use of docetaxel in the paediatric population in the indications breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma.
Slovenian: Zdravilo docetaksel ni primerno za uporabo pri pediatrični populaciji za indikacije rak dojke, nedrobnocelični pljučni rak, rak prostate, karcinom želodca in rak glave in vratu, ne vključujoč manj diferenciiran nazofaringealni karcinom tipa II oz. III.
English: These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4) and the COSTART terms and the MedDRA terms.
Slovenian: Neželeni učinki so bili opisani po merilih NCI Common Toxicity Criteria (3. stopnja = S3, 3.- 4. stopnja = S3/4, 4. stopnja = S4) in z izrazi COSTART in MedDRA.
English: Solvent: Polysorbate 80 and ethanol, anhydrous
Slovenian: Polisorbat 80 in etanol, brez vode
English: Additional cautions for use in adjuvant treatment of breast cancer For patients who experience complicated neutropenia (prolonged neutropenia, febrile neutropenia or infection), G-CSF and dose reduction should be considered (see section 4.2).
Slovenian: Dodatna opozorila pri uporabi adjuvantne terapije raka dojke Pri bolnicah, ki doživijo komplicirano nevtropenijo (podaljšano nevtropenijo, febrilno nevtropenijo ali okužbo) je potrebno razmisliti o G-CSF in zmanjšanju odmerka (glejte poglavje 4.2).
English: WHAT DOCEFREZ IS AND WHAT IT IS USED FOR
Slovenian: KAJ JE ZDRAVILO DOCEFREZ IN ZA KAJ GA UPORABLJAMO
English: In this study, 358 patients with inoperable locally advanced SCCHN, and WHO perfomance status 0 or 1, were randomized to one of two treatment arms.
Slovenian: V tej študiji so 358 bolnikov z inoperabilnim lokalno napredovalim SCCHN in stanjem zmogljivosti po WHO 0 ali 1 randomizirali v enega od dveh terapevtskih krakov.
English: Time to progressive disease was superior in the docetaxel + capecitabine combination arm (p<0.0001).
Slovenian: Čas do napredovanja bolezni je bil v kraku s kombinacijo docetaksel + kapecitabin boljši (p < 0,0001).
English: Survival was superior in the docetaxel +capecitabine combination arm (p=0.0126).
Slovenian: Preživetje je bilo boljše v kraku s kombinacijo docetaksel + kapecitabin (p = 0,0126).
English: • pain in the joints or muscles
Slovenian: • bolečine v mišičnih sklepih;
English: Docetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Slovenian: Docefrez je v kombinaciji s cisplatinom in 5-fluorouracilom indiciran za indukcijsko zdravljenje bolnikov z lokalno napredovalim skvamoznoceličnim karcinomom glave in vratu.
English: Alopecia was observed to be ongoing during follow-up in 25 patients out of the 736 patients with alopecia at the end of the chemotherapy.
Slovenian: Še prisotno alopecijo so pri spremljanju zabeležili pri 25 od 736 bolnicah, ki so imeli alopecijo ob koncu kemoterapije.